A jury in the US District Court of Eastern District of Texas decided on 8 April that the sale in the US of Daiichi Sankyo Co., Ltd./AstraZeneca PLC’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan; DS-8201) infringes Seagen Inc. ’s US patent 10,808,039.
The decision awarded damages of $41.82m for past infringement in the period leading up to trial and found there was...








